AML Therapy in Elders

Low-intensity outpatient consolidation therapy, rather than a single high-intensity regimen, led to a higher survival rate at 2 years.

More than 13,000 patients are diagnosed annually with acute myeloid leukemia (AML) in the U.S.; about half are older than 65. For those older patients who are able to undergo induction chemotherapy and who achieve complete remission (CR), the benefit of postremission consolidation has not been established nor has the optimal type been defined. In a prospective multicenter French trial, researchers addressed these concerns by randomizing newly diagnosed AML patients (age, ≥65) who achieved CR after induction chemotherapy to a single intensive consolidation cycle or to six cycles of low-intensity outpatient consolidation chemotherapy. The primary study endpoint was overall survival (OS) at 2 years.

Eligible patients had de novo AML or AML aris…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

AML Therapy in Elders

Topics

Reviewing Author